GUTS FRACTYL HEALTH, INC.
Executive Summary
Q3 2024 13F filings show mixed institutional activity in Fractyl Health (GUTS): four funds (Woodline Partners, Schwab, Rhumbline, Legal & General) added shares, but Norges Bank slashed its position by 68%, driving net institutional selling of ~$1.1M. The cluster suggests divergent views on the surgical-medical-device company's near-term prospects.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$1.1M
▲ Buyers (4)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Woodline Partners | ADD | +61.8% | $1.1M | -$45.7K |
| Schwab | ADD | +56.9% | $204.0K | -$15.4K |
| Rhumbline Advisers | ADD | +99.3% | $37.0K | $6.0K |
| Legal & General Group | DOUBLED | +209.3% | $8.0K | $4.0K |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Norges Bank | TRIM | -68.1% | $1.3M | -$1.1M |
Actionable Insight
The large Norges Bank trim may reflect strategic rebalancing or risk reduction, but the concurrent accumulation by multiple active asset managers (Woodline, Rhumbline, Legal & General) suggests a potential value or catalyst-based thesis. Combine with recent insider buying and strong analyst consensus (82% bullish) to gauge conviction. Monitor next earnings for fundamental catalyst that could resolve the divergent views.
Key Facts
- Norges Bank trimmed 68.1% of its GUTS holdings, selling ~213.5K shares and reducing its position from $1.3M to $253K.
- Woodline Partners added 61.8% (+160.4K shares), maintaining a $1.1M position.
- Schwab increased by 56.9% (+29.3K shares), Rhumbline Advisers by 99.3%, and Legal & General Group doubled its position.
- Four buyers added shares but total buyer value declined slightly to $1.3M due to stock price movement; the single seller's reduction dominated net dollar flow.
- Recent insider buying of $44K (two buys in last 30 days) provides a modest counterweight to institutional selling.
Financial Impact
Net institutional outflow of approximately $1.1M, with $1.3M in total buyer positions offset by $1.3M in seller divestment (primarily Norges Bank). Net dollar change across all filers is -$1.14M.
Risk Factors
- 13F data is 45+ days old and positions may have been unwound since quarter-end.
- Dominant seller (Norges Bank) is a sophisticated sovereign fund; their reduction may signal fundamental concerns not yet public.
- Small-cap medtech stocks face clinical/regulatory binary risks that could amplify moves in either direction.
Market Snapshot
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-GUTS-2024-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
4d ago
|
Institutional Cluster
| $0.8500 $0.8500 | · 0.00% | ▼ −1.76% | — |
|
Jun 11, 2026
5d ago
|
Insider Cluster
| $0.8500 $0.8500 | · 0.00% | ▼ −1.76% | — |
|
Jun 11, 2026
5d ago
|
Institutional Cluster
| $0.7239 $0.8500 | ▲ +17.42% | ▲ +16.88% | — |
|
Jun 4, 2026
12d ago
|
8-K
| $0.7340 $0.6790 | ▼ −7.49% | ▼ −4.89% | — |
|
Jun 4, 2026
12d ago
|
Press Release
| $0.7340 $0.6790 | ▼ −7.49% | ▼ −4.89% | — |
|
May 12, 2026
5w ago
|
8-K
| $0.9480 $0.9480 | · 0.00% | ▲ +0.00% | — |
|
May 12, 2026
5w ago
|
Press Release
| $0.9480 $0.9480 | · 0.00% | ▲ +0.00% | — |
|
May 11, 2026
5w ago
|
8-K
| $0.7690 $0.7340 | ▼ −4.55% | ▼ −4.41% | — |
|
May 11, 2026
5w ago
|
Press Release
| $0.7690 $0.7340 | ▼ −4.55% | ▼ −4.41% | — |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $0.6530 $0.6560 | ▲ +0.46% | ▲ +0.94% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access